Chronic Thromboembolic Pulmonary Hypertension Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32), Estimates DelveInsight | Actelion, Attgeno, SciPharm Sarl, Bayer
DelveInsight’s “Chronic Thromboembolic Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Thromboembolic Pulmonary Hypertension market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Chronic Thromboembolic Pulmonary Hypertension drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chronic Thromboembolic Pulmonary Hypertension treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chronic Thromboembolic Pulmonary Hypertension: An Overview
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, progressive pulmonary vascular disease characterized by macroscopic thromboembolic lesions (Blood clots) and microscopic pulmonary vascular changes. Clinically, CTEPH is defined as a mean pulmonary artery pressure ≥25 mmHg at rest persisting for at least 6 weeks in patients with previous Pulmonary artery embolism. The symptoms of CTEPH include Shortness of breath, Edema, fatigue, and Chest pain and are therefore similar to other, more common diseases, resulting in an often delayed diagnosis of CTEPH.
The optimal medical treatment for CTEPH consists of anticoagulants diuretics, and O2 in cases of heart failure or hypoxemia. Lifelong anticoagulation is recommended, even after PEA, though no data exist on the efficacy and safety of new oral anticoagulants. Pulmonary microvascular disease in CTEPH has provided the rationale for off-label use of drugs approved for PAH.25 Some non-randomized studies have provided evidence for improvement in exercise capacity and hemodynamics. The best and preferred treatment for CTEPH is a surgical procedure called pulmonary thromboendarterectomy (PTE) or pulmonary endarterectomy.
Chronic Thromboembolic Pulmonary Hypertension Market Key Facts
-
As per the study by Douglas et al. (2019), CTEPH occurs in 3 to 30 individuals per million general population per year and has been shown to be a long-term complication of pulmonary embolism with a cumulative incidence of 0.1% to 9.1% within 2 years after a symptomatic event.
-
According to Henning et al. (2016), In the USA and Europe, the crude annual incidence of diagnosed pulmonary embolism and crude annual full (i.e. diagnosed and undiagnosed) incidence of CTEPH was 66-104 and 3–5 cases per 100 000 population, respectively, while in Japan these rates were lower at 6.7 and 1.9 per 100 000 population, respectively.
-
According to Lang et al. (2021, CTEPH has been reported with a cumulative incidence of 0.1–9.1% within the first 2 years after a symptomatic PE event.
-
As per C. Martinz et al. (2018), women accounted for a higher percentage of CTEPH prevalent cases (54.1%) compared to males (45.9%).
Chronic Thromboembolic Pulmonary Hypertension Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Chronic Thromboembolic Pulmonary Hypertension pipeline therapies. It also thoroughly assesses the Chronic Thromboembolic Pulmonary Hypertension market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Chronic Thromboembolic Pulmonary Hypertension drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Chronic Thromboembolic Pulmonary Hypertension Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Chronic Thromboembolic Pulmonary Hypertension epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Chronic Thromboembolic Pulmonary Hypertension epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Chronic Thromboembolic Pulmonary Hypertension Epidemiology, Segmented as –
-
Total Chronic Thromboembolic Pulmonary Hypertension Prevalent Cases
-
Chronic Thromboembolic Pulmonary Hypertension Age-specific Cases
-
Chronic Thromboembolic Pulmonary Hypertension Gender-specific Prevalent Cases
-
Chronic Thromboembolic Pulmonary Hypertension Diagnosed
-
Treatable Cases in the Chronic Thromboembolic Pulmonary Hypertension
Chronic Thromboembolic Pulmonary Hypertension Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Chronic Thromboembolic Pulmonary Hypertension market or expected to be launched during the study period. The analysis covers the Chronic Thromboembolic Pulmonary Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Chronic Thromboembolic Pulmonary Hypertension drugs based on their sale and market share.
The report also covers the Chronic Thromboembolic Pulmonary Hypertension pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Chronic Thromboembolic Pulmonary Hypertension companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Chronic Thromboembolic Pulmonary Hypertension Market Will Evolve and Grow by 2032 @
Chronic Thromboembolic Pulmonary Hypertension Companies Actively Working in the Therapeutics Market Include
-
Actelion
-
Attgeno
-
SciPharm Sarl
-
Bayer
And Many Others
Emerging and Marketed Chronic Thromboembolic Pulmonary Hypertension Therapies Covered in the Report Include:
-
Macitentan: Actelion
-
Supernitro (PDNO): Attgeno
-
Treprostinil : SciPharm Sarl
-
Riociguat: Bayer
And Many More
The Report Covers an In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chronic Thromboembolic Pulmonary Hypertension Competitive Intelligence Analysis
4. Chronic Thromboembolic Pulmonary Hypertension Market Overview at a Glance
5. Chronic Thromboembolic Pulmonary Hypertension Disease Background and Overview
6. Chronic Thromboembolic Pulmonary Hypertension Patient Journey
7. Chronic Thromboembolic Pulmonary Hypertension Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Chronic Thromboembolic Pulmonary Hypertension Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Thromboembolic Pulmonary Hypertension Unmet Needs
10. Key Endpoints of Chronic Thromboembolic Pulmonary Hypertension Treatment
11. Chronic Thromboembolic Pulmonary Hypertension Marketed Therapies
12. Chronic Thromboembolic Pulmonary Hypertension Emerging Drugs and Latest Therapeutic Advances
13. Chronic Thromboembolic Pulmonary Hypertension Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Thromboembolic Pulmonary Hypertension Market Outlook (In US, EU5, and Japan)
16. Chronic Thromboembolic Pulmonary Hypertension Companies Active in the Market
17. Chronic Thromboembolic Pulmonary Hypertension Access and Reimbursement Overview
18. KOL Views on the Chronic Thromboembolic Pulmonary Hypertension Market
19. Chronic Thromboembolic Pulmonary Hypertension Market Drivers
20. Chronic Thromboembolic Pulmonary Hypertension Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Tongue Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Tongue Cancer market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Tongue Cancer market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology
, Estimates DelveInsight | Actelion, Attgeno, SciPharm Sarl, Bayer){kind=link}